Advertisement
Advertisement
Money /

Markets & Investing

Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Banking & finance

Hong Kong’s anticipated stablecoin licence by end-March does not materialise

videocam
IPO

Hong Kong retains IPO crown but may lose to US mega listings over full year

Mainland China

Sketching a recovery: China puts next-gen art buyers in the frame amid slowdown

A US$83 trillion global wealth transfer in next two to three decades is beginning to reshape China’s art market: UBS.

Tracey Emin’s “Take me to Heaven” on display at Art Basel in Hong Kong. Wealth managers are increasingly targeting a younger cohort when it comes to art investment. Photo: Enid Tsui
Tracey Emin’s “Take me to Heaven” on display at Art Basel in Hong Kong. Wealth managers are increasingly targeting a younger cohort when it comes to art investment. Photo: Enid Tsui
Turkey

As tensions rise, Middle Eastern money and travellers pivot to Hong Kong

Wealthy Gulf visitors are extending their stays in Hong Kong as investors from the region look to hedge risk and tap Asian markets.

Banking & finance

Tong Ren Tang unit pulls Hong Kong IPO in first postponement this year

Hospital-network operator delays plan to raise up to US$115 million amid tepid demand.

videocam
Advertisement
Advertisement
Advertisement
China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Semaglutide generated about US$35 billion in global revenue last year. Photo: AFP
Semaglutide generated about US$35 billion in global revenue last year. Photo: AFP
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Banking & finance

Asian private equity values cash flow as fundraising falls to 12-year low

Advanced manufacturing and healthcare attract more attention at the expense of technology, media and telecommunications, Bain & Co says.

Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
Banking & finance

Iran conflict drives fund managers to slash risk and hoard cash: BofA survey

Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.

Investor sentiment fell to a six-month low in March, according to a BofA report. Photo: AFP
Investor sentiment fell to a six-month low in March, according to a BofA report. Photo: AFP
Banking & finance

Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says

Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Hong Kong stock market

Hong Kong stocks edge higher as oil steadies, tracking Wall Street gains

Hang Seng Index advances for a second day amid easing concerns over inflation and geopolitical risks.

A motorist holds a fuel pump nozzle to fill up his car. Photo: AFP
Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
The latest applications come as healthcare and biotechnology equity capital market activity in Hong Kong reached US$15.6 billion last year. Illustration: Shutterstock
China stock market

Hopes of AI monetisation to boost China tech stocks amid war, market scares

Chinese tech stocks prove steadier than regional and US peers, as frenzy over OpenClaw shows a possible way forward, analysts say.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

Advertisement
Advertisement
Advertisement
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Overseas capital tends to cherry-pick a few big-cap pharmaceutical companies rather than buy the biotech sector broadly, according to an analyst. Photo: Handout
Millionaires and billionaires

Adrian Cheng maps out investment plan in line with China’s 5-year plan

The former CEO of NWD plans to spend more time in mainland China this year to scope out tech investment targets.

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
IPO

HSBC chairman floats ‘IPO connect’ for Hong Kong, Shenzhen listings

Modelled on Stock Connect, the proposal would give investors in the Greater Bay Area cross-border access to new share listings.

Bull statues are seen in front of the Shenzhen Stock Exchange on November 17, 2024. Photo: Getty Images
Bull statues are seen in front of the Shenzhen Stock Exchange on November 17, 2024. Photo: Getty Images
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Mainland China

China’s copper crash: from investment fad to scrap in a month

A brief speculative frenzy amid skyrocketing gold and silver prices leaves some retail investors holding shiny kilogram bars they can’t sell.

Copper bars were priced at a premium of as much as 200 per cent above the spot price of copper in January in China. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW